French vaccine manufacturer Valneva said on Jan. 19 that it is voluntarily withdrawing its U.S. applications seeking formal and investigational approval of its chikungunya vaccine.
The Food and Drug Administration in 2025 suspended a license it had granted Valneva’s vaccine, Ixchiq, because a review determined the vaccine was not safe. The review analyzed reports of health problems following vaccination, including among people who tested positive for chikungunya, a mosquito-borne virus.
